论文部分内容阅读
目的 :研究 10名健康志愿者口服都可喜 (阿米三嗪 /萝巴新 )后阿米三嗪和萝巴新的药动学。方法 :分别采用高效液相色谱法紫外检测器和高效液相色谱法荧光检测器测定血浆中阿米三嗪和萝巴新浓度。结果 :经 3P87药动学计算程序处理拟合 ,两者皆符合口服给药二室开放模型 ,其药动学参数为 :阿米三嗪的AUC为 (34 174.91± 2 335 .17) μg·h·L-1,tmax为 (3.81± 0 .76 )h ,cmax为 (816 .76± 70 .0 7) μg·L-1;萝巴新的AUC为 (1116 .15± 81.85 ) μg·h·L-1,tmax为 (1.2 7± 0 .2 2 )h ,cmax为(374.0 4± 71.71) μg·L-1。结论 :此研究为临床提供了药动学参数及生物利用度研究的方法。
OBJECTIVE: To study the pharmacokinetics of amilotriazine and radaprozin in 10 healthy volunteers after they were orally administered with dexamethasone (amilizine / rupivin). Methods: Plasma concentrations of amilotriazine and radapus were determined by high performance liquid chromatography with ultraviolet detector and high performance liquid chromatography with fluorescence detector respectively. Results: The 3P87 pharmacokinetic calculation program for the treatment of fitting, both in line with oral administration of two-compartment open model, the pharmacokinetic parameters: the AUC of amiltrazine (34 174.91 ± 2 335 .17) μg · h · L-1, tmax was (3.81 ± 0.76) h, cmax was (816.76 ± 70.077) μg · L-1, and the AUC of radorubin was (1116.15 ± 81.85) μg · h · L-1, tmax was (1.2 7 ± 0.22) h and cmax was (374.0 4 ± 71.71) μg · L -1. Conclusion: This study provides a clinical study of pharmacokinetic parameters and bioavailability methods.